(Reuters) - Gilead Sciences said on Friday it was voluntarily withdrawing the U.S. approval for Trodelvy in previously ...

The board of directors of (Nasdaq: RPRX) has approved the payment of a dividend for the fourth quarter of 2024 of $0.21 per Class A ordinary share. The dividend will be paid on December 10, 2024, to ...

We recently published a list of 8 High Growth UK Stocks to Invest In. In this article, we are going to take a look at where ...

Gilead Sciences GILD has outperformed the market over the past 20 years by 3.74% on an annualized basis producing an average ...

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, ...

As for Lilly ( LLY ), Bernstein said its outperform rating “hinges on what they can do with the cash they generate from ...

Companies with a long history of paying dividends and consistently hiking them remain appealing to income-focused investors.

The global pharmaceutical industry will generate more than $1.2 trillion in sales in 2025, according to Statista. A large portion of that figure is from the oncology segment, which is expected ...

These blue chip dividend stocks would be ideal for investors who had to hold them forever. They provide reliable streams of ...